Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects

NCT01702480 | Completed Phase 1

• 1 other identifier: 116713
• Study Type: interventional
• Target: 116
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single centre, 2 part study in older subjects. Part 1 (Pharmacokinetic \[PK\] Assessment) is a double blind, randomized, placebo-controlled 4-period crossover study investigating the PK profile of four different doses of GSK2981710. Eight subjects will receive a single dose of GSK2981710 10 gram (g), 20 g, 30 g, 40 g or placebo in the morning and have PK assessments (every 0.5 hrs up to 8 hrs post-dose) throughout the day in each period. Each subject will complete a total of four dosing sessions and 4 days of PK assessments in 2 weeks. The Part 1 PK data will be used for dose selection and pharmacodynamic (PD) assessment period in Part 2. If the data from Part 1 is inconclusive, an additional 8 subjects may be recruited and Part 1 repeated (possibly dropping some doses) to increase confidence. A subject's total participation in Part 1 of the study will last a maximum of approximately 7 weeks including screening. Subjects who have completed Part 1 may be screened for eligibility and enrolled for Part 2. Part 2 (PD Assessment) is a double blind randomized, placebo-controlled 2-period crossover design with 14-day treatment periods investigating the efficacy (cognitive performance) and tolerability (gastrointestinal \[GI\] side effects) of single daily dose of GSK2981710 selected from Part 1. Part 2 of the study will include the Screening period, two Baseline assessments (6-8 days before each Treatment period) and two 14-day treatment periods separated by a minimum 7-day washout period and follow-up visit of 3 to 5 days. Approximately 50 to 80 subjects will be randomized to either GSK2981710 or placebo. The PD assessments will be performed on 6 occasions for each subject: at 2 baselines (6 to 8 days before Day 1 of each treatment period), post-dose on the Day 1 of each treatment period to assess acute effects and on Day 15 of each treatment period (which is the day after the final dose) to assess chronic effects. A subject's total participation in Part 2 of the study will last approximately up to 12 weeks including screening.

Conditions

Alzheimer's Disease

Keywords

Consumer Healthcare; Ketones; Medium Chain Triglycerides; Age related cognitive decline; GSK Nutrition

Outcome Measures

Primary Outcomes (9)

• Part 1: Plasma BHB elevation time course of GSK2981710

  To select the dose of GSK2981710 that achieves the best PK profile, the duration of maximum elevation of beta-hydroxybutrate (BHB) will be measured.

  Baseline (Day 0 pre dose) and Day 1 post dose (per 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6, 6.5, 7, 7.5 and 8 hrs) of each of the 4 treatment periods.

• Part 1: Area under the time concentration curve (AUC) of GSK2981710

  To select the dose of GSK2981710 that achieves the best PK profile the AUC of GSK2981710 will be measured.

  Baseline (Day 0 pre dose) and Day 1 post dose (per 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6, 6.5, 7, 7.5 and 8 hrs) of each of the 4 treatment periods.

• Part 1: Maximum concentration (Cmax) of GSK2981710

  To select the dose of GSK2981710 that achieves the best PK profile the Cmax of GSK2981710 will be measured.

  Baseline (Day 0 pre dose) and Day 1 post dose (per 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6, 6.5, 7, 7.5 and 8 hrs) of each of the 4 treatment periods.

• Part 2: Change from Baseline in performance on CANTAB Paired Associates Learning task

  To measure acute (after single dose) and chronic (after two weeks daily dosing) effects of GSK2981710 on cognition and neural function Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used. This test assesses visual memory and new learning

  Baseline (Day 0) and Day 1 (post dose) and Day 15 (post dose) of both treatment periods.

• Part 2: Change from Baseline in performance on CANTAB Verbal Recognition Memory task

  To measure acute (after single dose) and chronic (after two weeks daily dosing) effects of GSK2981710 on cognition and neural function CANTAB will be used. This test assesses the participant's ability to recall as many of the words as possible immediately following the presentation of list of words.

  Baseline (Day 0) and Day 1 (post dose) and Day 15 (post dose) of both treatment periods.

• Part 2: Change from Baseline in performance on CANTAB Spatial Working Memory (SWM) task

  To measure acute (after single dose) and chronic (after two weeks daily dosing) effects of GSK2981710 on cognition and neural function CANTAB will be used. This test assesses the participant's ability to retain spatial information and to manipulate remembered items in working memory.

  Baseline (Day 0) and Day 1 (post dose) and Day 15 (post dose) of both treatment periods.

• Part 2: Change from Baseline in performance on CANTAB Rapid Visual Processing task

  To measure acute (after single dose) and chronic (after two weeks daily dosing) effects of GSK2981710 on cognition and neural function CANTAB will be used. This test assesses continuous performance and visual sustained attention.

  Baseline (Day 0) and Day 1 (post dose) and Day 15 (post dose) of both treatment periods.

• Part 2: Change from Baseline in performance on CANTAB Reaction Time task

  To measure acute (after single dose) and chronic (after two weeks daily dosing) effects of GSK2981710 on cognition and neural function CANTAB will be used. This test measures of attention, and combines simple reaction time and choice reaction time elements

  Baseline (Day 0) and Day 1 (post dose) and Day 15 (post dose) of both treatment periods.

• Part 2: Change from Baseline in performance on Source Memory Task

  This test measures the participant's ability to recognize objects previously presented on a computer screen, and more importantly, to recall the spatial location of those objects.

  Baseline (Day 0) and Day 1 (post dose) and Day 15 (post dose) of both treatment periods.

Secondary Outcomes (10)

• Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by number of subjects with adverse events (AE)s

  Part 1: 3 weeks; Part 2: 8 weeks

• Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in ECG readings

  Part 1: Baseline and 3 to 5 days post last dose in each of the 4 treatment periods.

• Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in laboratory values

  Part 1: Baseline and 3 to 5 days post last dose in each of the 4 treatment periods.

• Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in vital signs

  Part 1: Baseline and 3 to 5 days post last dose in each of the 4 treatment periods.

• Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by Gastrointestinal (GI) Symptom and stool diary

  Part 1: Day -7 until Day 49.

Study Arms (7)

Part 1: GSK2981710 10 gram (g)

EXPERIMENTAL

Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.

Drug: GSK2981710

Part 1: GSK2981710 20 g

EXPERIMENTAL

Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.

Drug: GSK2981710

Part 1: GSK2981710 30 g

EXPERIMENTAL

Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.

Drug: GSK2981710

Part 1: GSK2981710 40 g

EXPERIMENTAL

Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.

Drug: GSK2981710

Part 1: Placebo

PLACEBO COMPARATOR

Eight subjects will receive single dose of matching placebo daily for 14 days.

Drug: Placebo

Part 2: GSK2981710 (dose to be decided from Part 1)

EXPERIMENTAL

The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.

Drug: GSK2981710

Part 2: Placebo

PLACEBO COMPARATOR

The subjects will receive single dose of matching placebo daily for 14 days..

Drug: Placebo

Interventions

GSK2981710 DRUG

Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast

Part 1: GSK2981710 10 gram (g); Part 1: GSK2981710 20 g; Part 1: GSK2981710 30 g; Part 1: GSK2981710 40 g; Part 2: GSK2981710 (dose to be decided from Part 1)

Placebo DRUG

Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast

Part 1: Placebo; Part 2: Placebo

Eligibility Criteria

• Age: 55 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female individuals between the ages of 55 years and 80 years inclusive.
• A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. Child-bearing potential and has a negative pregnancy test on each of the testing visits.
• Body weight \>=50 kilogram (kg) in males and \>=40 kg in females. Body mass index (BMI) in the range 18.0 to 29.9 kg/meter (m)\^2.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• Sufficiently fluent in English that they are able to understand written and spoken instructions in the opinion of the investigator.
• Supine blood pressure between 110/70 to 150/90 millimetres of mercury (mmHg) inclusive at screening. Patients with a current history of hypertension who are controlled on a stable regimen for at least 3 months prior to the study and are asymptomatic can be included.
• lead electrocardiogram (ECG) without any clinically significant abnormality as judged by the Investigator, and QT interval corrected using Bazett's formula (QTcB) or QT interval corrected using Fridericia's formula (QTcF) \<=450 millisecond (msec)
• Suitable for cannulation and with adequate venous access
• Aspartate aminotransferase (AST), Alanine transaminase (ALT), alkaline phosphatase and bilirubin \<= 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
• For Part 2: Performs below the cut-off level on the Wechsler logical memory test below the mean level of performance of young, healthy adults.
• For Part 2: Otherwise normal neuropsychological performance as indicated by performance above the required level on the MINI Mental State Examination (MMSE) (a score of 27 or above is eligible).

You may not qualify if:

• Previous or current medical condition, which as judged by the Investigator with consultation with the GSK Medical Monitor if required, may compromise subject safety or may interfere with the study procedures or the interpretation of data..
• Learning disability or learning disorder.
• Current history of Axis I psychiatric disorder as determined by MINI interview
• A drug dependence by the Diagnostic and Statistical Manual of Mental Disorders, Fourth (DSM-IV) criteria within the last 6 months as assessed by the Mini-international neuropsychiatric interview (MINI).
• A fall of at least 20 mm Hg systolic blood pressure within three minutes of standing upright at screening
• A positive pre-study human immunodeficiency virus (HIV), Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
• History of alcohol or substance abuse or dependence in the 6 months prior to screening as determined by the investigator. Abuse of alcohol, defined for males, as an average weekly intake of greater than 21 units (or an average daily intake of greater than 3 units), or defined for females, as an average weekly intake of greater than 14 units (or an average daily intake of greater than 2 units). One unit is equivalent to a half-pint (220 milliliters \[mL\]) of beer or 1 (25 mL) measure of spirits or 1 glass (125 mL) of wine.
• Current smokers defined as regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
• Positive urine drug or alcohol breath test at screening or when tested at any of the study visits.
• Lactating females or pregnant females as determined by a positive urine/serum human chorionic gonadotropin (hCG) test at screening or when tested at any of the study visits.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the testing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Lactose intolerant or allergic to milk or soy products
• The subject is on a diet including any diet that restricts or modifies intake of a particular type of food, e.g. carbohydrates, proteins, fats, or is on a ketogenic diet.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Cambridge, Cambridgeshire, CB2 2GG, United Kingdom

Location

Related Links

• Results for study 116713 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Alzheimer Disease; Ketosis

Interventions

GSK2981710

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Acidosis; Acid-Base Imbalance; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 4, 2012
• First Posted: October 8, 2012
• Study Start: November 5, 2012
• Primary Completion: July 3, 2015
• Study Completion: July 3, 2015
• Last Updated: May 9, 2017

Record last verified: 2017-05

Locations

GB (1)